Skip to main content
Premium Trial:

Request an Annual Quote

Mesa Biotech Receives 510(k) Clearance, CLIA Waiver for Strep A Molecular Point-of-Care Test

NEW YORK ─ Mesa Biotech said on Wednesday it has received US Food and Drug Administration 510(k) clearance and a CLIA waiver for its Accula Strep A molecular test.

The firm said that its visually-read Strep A cassette, which fits in the palm of a hand, has been cleared for the detection of Group A Streptococcus bacterial nucleic acid to diagnose children and adults.

Accula Strep A uses RT-PCR to detect Strep A using throat, nasal, or nasopharyngeal swab samples and provides results in 30 minutes at the point of care, Mesa Biotech added.

"Our Accula testing platform enables healthcare providers to reach a rapid diagnosis and administer the appropriate treatment, thus reducing the amount of time the patient is sick, preventing long-term health problems, and helping prevent the spread of infection," Hong Cai, cofounder and chief technology officer of Mesa Biotech, said in a statement.

Accula Strep A is the third molecular POC diagnostic test on the Mesa Biotech Accula platform to receive FDA clearance and a CLIA waiver, after tests for Flu A/Flu B and RSV.

San Diego-based Mesa received Emergency Use Authorization for its SARS-CoV-2 cassette earlier this year.

In November, the company announced a $13 million award from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) for the development of a rapid point-of-care test for SARS-CoV-2 and influenza.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.